Cystathionine γ-Lyase Identified as a Key Regulator of Memory and Learning
January 1, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Leukotac
Synonyms :
inolimomab
Class :
Interleukin Inhibitors, Immunologic
Brand Name :
Leukotac
Synonyms :
inolimomab
Class :
Interleukin Inhibitors, Immunologic
Chronic Graft-versus-host Disease
FDA approval pending for steroid-refractory acute graft-versus-host disease (aGvHD) for grade 2 to 4
Contraindicated
Refer to adult dosing
Actions and Spectrum
The CD25 antigen, which is expressed by activated T cells, especially those involved in graft-versus-host disease (GvHD), is the target of inolimomab’s action. Inolimomab prevents these T cells from becoming activated and from multiplying by attaching to CD25.
The immune response underlying GvHD is precisely targeted and modulated by inolimomab. In adult patients, it is primarily approved for the treatment of acute steroid-resistant or steroid-dependent GvHD.
None
Black Box Warning:
None
Contraindication/Caution:
None
Pregnancy warnings:
Pregnancy category: N/A
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
inolimomab is a monoclonal antibody that specifically targets and binds to a protein known as CD25, which is expressed as activated T-lymphocytes. CD25 is a subunit of the interleukin-2 (IL-2) receptor, and its binding is involved in the activation and proliferation of T-lymphocytes.
By binding to CD25, inolimomab inhibits the binding of IL-2 to its receptor and subsequently disrupts the IL-2 signaling pathway.
Pharmacodynamics
The intended pharmacodynamic effects of inolimomab include a reduction in T-lymphocyte activation and proliferation. By blocking IL-2 signalling, inolimomab aims to dampen the immune response, specifically in the context of graft-versus-host disease (GvHD) following stem cell or bone marrow transplant.
Pharmacokinetics
Absorption
inolimomab is administered intravenously, which ensures rapid and complete absorption of the medication into the systemic circulation.
Distribution
inolimomab is expected to distribute throughout the body, including the extravascular spaces.
Metabolism
The metabolism of inolimomab has yet to be studied or documented.
Elimination and Excretion
The excretion pathway of inolimomab has yet to be well defined.
Administration
inolimomab is typically administered through the intravenous (IV) route.
Patient information leaflet
Generic Name: inolimomab (Pending FDA Approval)
Why do we use inolimomab?
inolimomab has mainly been researched for its possible application in treating graft-versus-host disease (GvHD).
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
